New promising treatment for children with ADHD shows improved efficiency

A new study on dasotraline in children aged 6 to 12 years, a promising new treatment for Attention Deficit Hyperactivity Disorder (ADHD), has shown a significant improvement in blood pressure. efficacy of ADHD treatment compared to placebo starting at week 1 and continuing throughout the study. A detailed description of the design of the test and the results is published in the Journal of psychopharmacology for children and adolescents, a peer-reviewed journal of Mary Ann Liebert, Inc., Publishers.

Robert Goldman, PhD, Sunovion Pharmaceuticals (Marlborough, MA and Fort Lee, NJ), and colleagues at the Kennedy Krieger Institute / Johns Hopkins University (Baltimore, MD), Langone Medical Center of New York University (NY, NY) and Mbadachusetts General Hospital (Boston, MA) the article titled "Dasotraline in Children with Hyperactivity Disorder or Hyperactivity: a Placebo-Controlled Fixed-Dose Trial of Six Weeks" .

The researchers conducted a six-week trial in which children diagnosed with ADHD received a daily morning dose of dasotraline (2mg or 4mg) or placebo. The primary endpoint for determining effectiveness was an ADHD rating scale that determined the change from baseline. Treatment with dasotraline at only 4 g / day was badociated with a significant improvement in efficacy. Dasotraline also showed significant improvement for some secondary endpoints, including measures of hyperactivity and inattention. The study also evaluated the safety of dasotraline treatment and performed a subgroup badysis to investigate differences in safety and efficacy between subgroups, such as age, bad and the use of other treatments for ADHD.

"More than four million children suffer from ADHD, and research into new safe treatments, with fewer side effects, is needed for this group of patients," he said. Harold S. Koplewicz, MD, Editor-in-chief of Journal of psychopharmacology for children and adolescents and president of the Child Mind Institute in New York.